Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

Kenvue Reports Decline in Q4 Net Income


Kenvue, the pharmaceutical company known for producing popular brands such as Tylenol and Benadryl, experienced a slight decrease in fourth-quarter net income. The delayed start of the flu season in 2023 complicated comparisons with the previous year’s earnings.

In the fourth quarter, Kenvue reported earnings of $327 million, or 17 cents a share, compared to $361 million, or 21 cents a share, in the same period last year. Adjusted for certain one-off items, their earnings for the quarter stood at 31 cents a share, surpassing the average Wall Street expectation of 28 cents a share according to FactSet.

However, fourth-quarter sales saw a decline of 2.7%, amounting to $3.7 billion. This fell slightly short of the average analyst target of $3.78 billion as per FactSet’s data.

Industry analysts at UBS had previously warned about the impact of a delayed flu season in 2023 on Kenvue’s business, as well as the challenges faced by their Japanese heritage brands in China.

Providing a glimpse into its future prospects, Kenvue projected adjusted earnings for the year 2024 in the range of $1.10 to $1.20 per share, a decrease from $1.29 per share in 2023. The company also predicted sales growth between 1% and 3% from its 2023 sales of $15.4 billion, equating to a range of $15.55 billion to $15.86 billion. Excluding the impact of foreign exchange, organic sales growth for the year 2024 was estimated to fall between 2% and 4%.

Unibail-Rodamco-Westfield Reports Strong Performance and Raises Guidance for 2024

Previous article

Tapestry Stock Climbs as Earnings Outlook is Raised

Next article

You may also like


Leave a reply

Your email address will not be published.

More in News